Erin Quirk, M.D. is President, Chief Medical Officer, and Head of Research & Development at Terns Pharmaceuticals, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH).